Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

被引:0
|
作者
Krishnamurthy, Anuradha [1 ,2 ]
Wang, Hong [3 ]
Rhee, John C. [4 ]
Davar, Diwakar [2 ]
Moy, Ryan H. [5 ]
Ratner, Lee [6 ]
Christner, Susan M. [1 ]
Holleran, Julianne L. [1 ]
Deppas, Joshua [1 ,7 ]
Sclafani, Carina [8 ]
Schmitz, John C. [1 ]
Gore, Steve [9 ]
Chu, Edward [10 ]
Bakkenist, Christopher J. [8 ]
Beumer, Jan H. [1 ,3 ,4 ,11 ]
Villaruz, Liza C. [1 ,2 ]
机构
[1] UPMC, Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA
[4] UPMC, Hillman Canc Ctr, Pittsburgh, PA 15232 USA
[5] Columbia Univ, Irving Med Ctr, Dept Med, Div Hematol & Oncol, New York, NY USA
[6] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[7] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA USA
[8] Univ Pittsburgh, UPMC, Sch Med,Hillman Canc Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[9] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD USA
[10] Albert Einstein Coll Med, Bronx, NY USA
[11] Univ Pittsburgh, Canc Inst, Canc Inst, Room G27E,5117 Ctr Ave, Pittsburgh, PA 15213 USA
关键词
Elimusertib; BAY; 1895344; FOLFIRI; Pharmacokinetics; ATR inhibition; DNA-DAMAGE RESPONSE; ADVANCED SOLID TUMORS; COLORECTAL-CANCER; KINASE INHIBITOR; IRINOTECAN; COMBINATION; FLUOROURACIL; MULTICENTER; CISPLATIN; THERAPY;
D O I
10.1007/s00280-024-04745-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models.MethodsTo establish dose and tolerability of elimusertib with FOLFIRI, a Bayesian Optimal Interval trial design was pursued. Starting elimusertib dose was 20 mg BID days 1, 2, 15 and 16 every 28-day cycle, combined with irinotecan (150 mg/m2) and 5-FU (2000 mg/m2).ResultsThe trial was stopped after 10 accruals, with four DLT across 4 dose levels including grade 3 febrile neutropenia, mucositis, nausea, vomiting and grade 4 neutropenia. The most common grade 3/4 adverse events were neutropenia, leukopenia, lymphopenia and mucositis. Based on significant toxicities the trial was stopped. PK data for 5-FU and irinotecan were unremarkable and did not account for DLTs. Among the six response evaluable patients, four had stable disease as their best response. Median PFS was 7 months. A first case of ATRi chemotherapy combination related AML (t-AML) was observed.ConclusionsThe combination of elimusertib with FOLFIRI was associated with intolerable toxicity. Combination of ATR kinases with chemotherapies that target DNA replication may be associated with significant myelotoxicity. Ongoing ATRi trials should monitor for t-AML.ClinicalTrials.gov IDNCT04535401
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
    Peter S. Galatin
    Ranjana H. Advani
    George A. Fisher
    Brian Francisco
    Thomas Julian
    Raquel Losa
    Marta I. Sierra
    Branimir I. Sikic
    Investigational New Drugs, 2011, 29 : 971 - 977
  • [32] A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol
    Dickson, M. A.
    Carvajal, R. D.
    Shah, M.
    Tse, A. N.
    Dials, H.
    Cane, L. M.
    Schwartz, G. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma
    Leibrandt, Ryan
    Frankel, Paul Henry
    Beumer, Jan Hendrik
    Takebe, Naoko
    Yin, Ming
    Emamekhoo, Hamid
    Lara, Primo Lucky N.
    Gore, Steven
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects
    Yap, Timothy A.
    Tan, David S.
    Stathis, Anastasios
    Shapiro, Geoffrey I.
    Iwasa, Satoru
    Joerger, Markus
    Zhang, Jingsong
    Plummer, Ruth
    Sawyer, Michael
    Tan, Aaron C.
    Castonguay, Vincent
    Gabrail, Nashat
    Matsubara, Nobuaki
    Wilkinson, Gary
    Ludwig, Matthias
    Zhou, Yinghui
    Merz, Claudia
    Hreiki, Joseph
    Sharma, Neelesh
    Debono, Johan
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Phase I trial of AT-101, an orally bioavailable inhibitor of BCL-2, in patients with advanced malignancies.
    Saleh, M
    Pitot, H
    Hartung, J
    Holmlund, J
    LoBuglio, A
    Forero, A
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9121S
  • [36] Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
    Caimi, Paolo F.
    Cooper, Brenda W.
    William, Basem M.
    Dowlati, Afshin
    Barr, Paul M.
    Fu, Pingfu
    Pink, John
    Xu, Yan
    Lazarus, Hillard M.
    de Lima, Marcos
    Gerson, Stanton L.
    ONCOTARGET, 2017, 8 (45) : 79864 - 79875
  • [37] ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1/2a Trial (ABOYA-119)
    Mahipal, A.
    LoRusso, P.
    Schneider, R.
    Miller, C.
    Stenehjem, D.
    Gullbo, J.
    Brown, E.
    Carleton, M.
    Mirza, N.
    Simpkins, F.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S131 - S131
  • [38] A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
    Piha-Paul, Sarina A.
    Dumbrava, Ecaterina E.
    Nair, Binoj C.
    Xiong, Wendy
    Xu, Li
    Mostorino, Rosa
    Subbiah, Vivek
    Tannir, Nizar
    Fu, Siqing
    Naing, Aung
    Janku, Filip
    Karp, Daniel D.
    Patel, Shreyaskumar
    Daw, Najat C.
    Hong, David
    Meric-Bernstam, Funda
    Zinner, Ralph
    ONCOTARGETS AND THERAPY, 2021, 14 : 3037 - 3049
  • [39] A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies.
    Friedman, DT
    Goel, S
    Desai, K
    Verdier-Pinard, D
    Kaubisch, A
    Bulgaru, A
    Camacho, F
    Goldberg, G
    Mani, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 155S - 155S
  • [40] Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies
    Goss, PE
    Reid, CL
    Bailey, D
    Dennis, JW
    CLINICAL CANCER RESEARCH, 1997, 3 (07) : 1077 - 1086